# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $...
HC Wainwright & Co. analyst Douglas Tsao maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price t...
Goldman Sachs analyst Salveen Richter maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target f...
RBC Capital analyst Brian Abrahams maintains Sage Therapeutics (NASDAQ:SAGE) with a Sector Perform and lowers the price targ...
Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and lowers the price target from $2...
Mizuho analyst Uy Ear maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $20 to $18.
Canaccord Genuity analyst Sumant Kulkarni maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and lowers the price target ...
Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Hold.
Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Hold.